ST Pharm & Quantoom Biosciences Announce First Supply Agreement of SmartCap Under Extended Collaboration to Advance RNA Manufacturing

ST Pharm and Quantoom Biosciences recently announced an extended collaboration to accelerate the development and manufacturing of RNA-based vaccines and therapeutics. This collaboration brings together complementary expertise to enhance the global supply of critical RNA manufacturing technologies, with a first supply agreement of ST Pharm’s proprietary 5’-capping reagent, SmartCap.

By combining their respective strengths and expertise, ST Pharm and Quantoom aim to expand their global reach and provide comprehensive solutions to the RNA manufacturing market. This partnership will enable both companies to leverage their technologies more effectively, accelerating the development and production of innovative RNA-based therapies.

This initial collaboration paves the road to an extended partnership in which ST Pharm’s proprietary and advanced IVT-based mRNA-LNP platform, including novel capping and formulation reagents, will be made available with Quantoom’s Ntensify and Ncapsulate mRNA production platform, with the aim to create a more robust and flexible RNA manufacturing ecosystem.

As a CDMO, ST Pharm will gain valuable insights into Quantoom’s Ntensify mRNA production processes, while Quantoom will benefit from the expanded capabilities enabled by ST Pharm’s unique technologies which will result in unprecedented levels of manufacturing flexibility for its customers.

“We are excited to partner with Quantoom Biosciences to advance the field of RNA therapeutics,” said Mooje Sung, CEO at ST Pharm. “This collaboration represents a significant step forward in our mission to provide cutting-edge and competitive RNA technologies to the global market. By combining our strengths, we can accelerate the development of life-changing RNA-based therapies.”

José Castillo, CEO at Quantoom Biosciences, added “This collaboration with ST Pharm marks a significant step forward for Quantoom and our Ntensify platform. By securing access to ST Pharm’s unique technologies, we are empowering our clients with unparalleled flexibility and control over their mRNA production processes. This partnership is a testament to our commitment to delivering cutting-edge solutions that drive innovation in the mRNA therapeutics space.”

ST Pharm is a top-tier CMO/CDMO with an integrated technology platform supporting clinical- and commercial-scale production of next-generation therapeutics in oligonucleotides, mRNA, and circRNA. ST Pharm’s nucleic acid platform includes process development, analytical development, and manufacturing services that are enhanced by the supply of critical raw materials such as nucleotides, phosphoramidites, and capping reagents, as well as leading RNA delivery solutions including lipid nanoparticle (LNP) and polyplex. ST Pharm is wholly committed to advancing life-saving nucleic acid medicines for patients around the world.

Quantoom Biosciences is leading the revolution in mRNA-based vaccines by offering turnkey solutions for mRNA-LNP manufacturing. Its cutting-edge Ntensify technology enables the production and purification of mRNA through a fully integrated, scalable system that combines processes, equipment, reagent mixes, and disposables. This solution supports the entire spectrum of mRNA production, from R&D to commercial manufacturing. Launched in 2023, Ntensify has already been widely adopted across multiple continents, showcasing its global appeal. Quantoom Biosciences is also developing the Ncapsulate technology for mRNA-LNP formulation and purification, aiming to significantly increase the accessibility and affordability of mRNA-based vaccines. Located in Belgium, Quantoom Biosciences thrives in a dynamic biotech ecosystem, driving innovation in mRNA production to make life-changing therapies available to everyone, everywhere.